Novo Nordisk said April 14 that it formed a strategic partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, supply chains, and commercial operations.
The Danish drugmaker said the goal is to speed research, analyze large biological datasets, and bring treatments to patients sooner. Pilot programs are starting immediately, and full integration into core workflows is expected by the end of 2026.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare,” the company said.
According to Novo Nordisk’s press release, the partnership will use AI to identify drug candidates, support manufacturing efficiency, and improve supply chain and commercial operations. OpenAI will also help train Novo Nordisk’s global workforce in AI literacy.
Novo Nordisk said the arrangement includes data governance and human oversight to support ethical and compliant use. OpenAI CEO Sam Altman said AI can help “people live better, longer lives” in life sciences.
The agreement comes as Novo Nordisk and Eli Lilly compete in obesity and diabetes treatments. Novo Nordisk built its business around glucagon-like peptide-1, or GLP-1, medicines, but the gap with Eli Lilly has narrowed.
Eli Lilly won U.S. approval earlier this month for its weight-loss pill Foundayo. Novo Nordisk launched an oral version of Wegovy in January 2026. Analysts forecast the global weight-loss drug market could top $100 billion in annual revenue over the next decade.
Eli Lilly also announced a partnership with Insilico Medicine in March 2026 to develop and commercialize AI-discovered medicines, according to Euronews.
Novo Nordisk said it plans to combine OpenAI’s models with its existing AI capabilities, including the Gefion AI supercomputer and internal scientific expertise.